In 2015, Nipro Corporation acquired lnfraredx, a U.S. Imaging Company, as part of its long-term strategic plan to build a world class cardiovascular brand.

Founded in 1954, Nipro is a publicly-traded (Token SE) company with revenue of $3.25 billion and an operating income of more than $260 million. Nipro Corporation offers products and technologies that meet the needs of patients and medical professionals in a wide range of fields, such as artificial organs, circulatory devices, test/diagnostic agents, injection/infusion solutions, ethical pharmaceuticals, and medical glass products. The agreement combines the strengths of Nipro Corporation and Infraredx, by leveraging Nipro’s strong global cardiovascular portfolio and resources along with Infraredx’s industry expertise in near infrared spectroscopy (NIRS) and intravascular ultrasound (IVUS). The agreement will help introduce Nipro’s cardiovascular product line into the United States, and continue Infraredx’s mission to empower interventional cardiologists with the advanced imaging tools required to predict heart attacks and prevent them—catalyzing a global shift from reactive treatment to proactive care of coronary artery disease.

Click the button to learn more about the Nipro product portfolio.

LEARN MORE

Nipro Company is headquartered in Osaka, Japan
3-9-3 HONJO-NISHI, KITA-KU, OSAKA 531-8510, JAPAN

Infraredx, Inc.

34 Third Avenue
Burlington, MA 01803 USA
+1.888.680.REDX (7339)

References
1 Detection by NIRS of LCPs at Culprit Sites in Patients with Acute STEMI, Madder et al, JACC Cardiovasc Interv. 2013
2 Detection of LCPs by intracoronary NIRS Identifies High Risk of Periprocedural MI, Goldstein et al, Circ Cardiovasc Interv. 2011